ArticleJournal of veterinary internal medicine
Effects of Plasma and Hetastarch Administration on Colloid Oncotic Pressure and Coagulation Variables in Dairy Calves and Goats.
Article in Journal of veterinary internal medicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Blood-Based Versus Crystalloid Cardiopulmonary Bypass Priming in Left Ventricular Assist Device Surgery: Impact on End-Organ Function and Survival.Interdisciplinary cardiovascular and thoracic surgery · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundTransfusion with fresh frozen plasma (FFP) or hetastarch 6% (HES) is an option for managing decreased colloid oncotic pressure (COP) associated with hypoproteinemia. The effectiveness of HES compared to plasma has not been reported in calves and goats. HYPOTHESIS: Hetastarch increases COP to levels similar to FFP. There will be no significant adverse clinicopathological changes after administration of HES. ANIMALS: Seven healthy preweaned calves and 7 juvenile goats from university herds.
methodsCohort, clinical trial in a two-way crossover design. Hetastarch and FFP were administered intravenously at 10 and 20 mL/kg, respectively, once. Plasma COP was measured re-transfusion, at 0, 1, 2, 4, 6, 12, 24, 36, 72 h, and 7 days after each transfusion. Coagulation variables were analyzed pre-transfusion, at 0, 24, and 72 h after transfusion. The effects of treatment and time on COP and coagulation variables were determined by multivariate analysis of variance.
resultsTransfusion with FFP and HES increased the COP in calves and goats, with FFP increasing the COP to a greater magnitude in calves (least square mean difference of 1.6 vs. 1 mmHg; p = 0.03) but not in goats (least square mean difference of 3.0 vs. 3.0 mmHg; p = 0.99). There were no significant changes (p > 0.05) in coagulation variables detected after transfusion with FFP or HES. CONCLUSIONS AND CLINICAL IMPORTANCE: Hetastarch is an alternative colloid to FFP in calves and goats. Adverse changes were not observed in goats and calves after HES administration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.